Wednesday, 12 August 2020

IQVIA teams up with AstraZeneca to support COVID-19 vaccine development

16 July 2020 | News

This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project

Image credit- shutterstock.com

Image credit- shutterstock.com

Leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry IQVIA has announced its collaboration with AstraZeneca to accelerate development of a potential new vaccine for COVID-19.

This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.

Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca’s potential COVID-19 vaccine, AZD1222.

This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA’s Virtual Trial solutions including Study Hub.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account